U.S. FDA Sets Advisory Date For MGI/Eisai's Aquavan
This article was originally published in PharmAsia News
Executive Summary
An FDA advisory committee in May will review MGI Pharma/Eisai's sedative hypnotic agent Aquavan, a drug eagerly awaited by health insurers looking to cut anesthetic costs in colonoscopy.
You may also be interested in...
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).